Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + LDAC in Treatment-Naïve AML
NCT02287233Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2014
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Dec 2014; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02287233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287233.